AI Engines For more Details: Perplexity Kagi Labs You
Antiprotozoal Activity: Diclazuril is a member of the triazine class of antiprotozoal drugs, which exert their therapeutic effects by interfering with the metabolism and reproduction of protozoa such as Eimeria species. Diclazuril targets the intracellular stages of the coccidian parasites, preventing their development and replication within host cells.
Treatment of Coccidiosis: Diclazuril is highly effective in the treatment of coccidial infections in animals, including poultry (chickens, turkeys), cattle, sheep, goats, pigs, and other species. It helps reduce the severity of clinical signs associated with coccidiosis, such as diarrhea, dehydration, lethargy, and poor growth or weight gain, leading to improved health and productivity in affected animals.
Prevention of Coccidiosis: In addition to its therapeutic use, diclazuril is also used for the prevention of coccidial infections in animals raised in intensive farming systems, such as commercial poultry production. Prophylactic treatment with diclazuril can help reduce the risk of coccidiosis outbreaks and minimize economic losses associated with decreased feed efficiency, poor growth rates, and increased mortality in infected animals.
Broad-Spectrum Activity: Diclazuril exhibits broad-spectrum activity against various species and strains of Eimeria parasites that commonly infect domestic animals. It is effective against both sensitive and resistant strains of coccidia, making it a valuable tool for controlling coccidial infections in livestock and poultry populations.
Ease of Administration: Diclazuril is typically administered orally to animals, either in the form of medicated feed, drinking water, or oral suspensions. It is well-absorbed from the gastrointestinal tract and rapidly distributed throughout the body, reaching therapeutic concentrations in target tissues where coccidial parasites reside.
Safety and Tolerability: Diclazuril is generally safe and well-tolerated in animals when administered at recommended dosages. Adverse effects are rare but may include mild gastrointestinal upset (e.g., vomiting, diarrhea) or allergic reactions in sensitive individuals. Proper dosing and administration practices should be followed to minimize the risk of adverse effects and ensure optimal therapeutic outcomes.
Regulatory Considerations: Diclazuril is approved for veterinary use in many countries worldwide and is available in various formulations and concentrations for use in different animal species and production systems. Veterinary oversight and prescription may be required for the use of diclazuril in some jurisdictions, particularly in commercial farming operations.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| ADHD | 3.6 | 0.3 | 11 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.5 | 1.4 | 0.79 |
| Allergies | 4.1 | 2.3 | 0.78 |
| Allergy to milk products | 1.6 | 1.3 | 0.23 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 5.1 | 6.1 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 0.9 | 1.33 |
| Ankylosing spondylitis | 3.4 | 1.8 | 0.89 |
| Anorexia Nervosa | 1.4 | 3.2 | -1.29 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 3.5 | 1.1 | 2.18 |
| Atherosclerosis | 2 | 1.9 | 0.05 |
| Atrial fibrillation | 2.9 | 2.6 | 0.12 |
| Autism | 7.7 | 7.4 | 0.04 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.6 | 2.6 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 1.1 | 1.1 | |
| Cancer (General) | 0.6 | 1.3 | -1.17 |
| Carcinoma | 3.4 | 1.4 | 1.43 |
| Celiac Disease | 2.7 | 2 | 0.35 |
| Cerebral Palsy | 0.8 | 1.3 | -0.63 |
| Chronic Fatigue Syndrome | 5.1 | 5 | 0.02 |
| Chronic Kidney Disease | 3 | 2.1 | 0.43 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.7 | 0.18 |
| Chronic Urticaria (Hives) | 1.6 | 1.2 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 1.7 | 1.3 | 0.31 |
| Colorectal Cancer | 6.1 | 1.9 | 2.21 |
| Constipation | 1.6 | 0.7 | 1.29 |
| Coronary artery disease | 2.6 | 2.5 | 0.04 |
| COVID-19 | 6.9 | 8.8 | -0.28 |
| Crohn's Disease | 7.5 | 4.2 | 0.79 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.2 | 1 | 0.2 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 8.6 | 6.4 | 0.34 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 2 | 1.1 | 0.82 |
| Endometriosis | 2.6 | 2.3 | 0.13 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.4 | 1.5 | 1.27 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2.5 | 2.3 | 0.09 |
| Functional constipation / chronic idiopathic constipation | 5.4 | 3.8 | 0.42 |
| gallstone disease (gsd) | 3.4 | 0.8 | 3.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.9 | 0.67 |
| Generalized anxiety disorder | 3 | 1.1 | 1.73 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.5 | 1 |
| Graves' disease | 1 | 1.8 | -0.8 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 2.5 | 1.2 | 1.08 |
| Heart Failure | 5.1 | 1.3 | 2.92 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
| hypercholesterolemia (High Cholesterol) | 1 | 1 | |
| hyperglycemia | 1.2 | 0.9 | 0.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.3 | 4 | -0.21 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 2.7 | 2.7 | |
| IgA nephropathy (IgAN) | 1.6 | 4.1 | -1.56 |
| Inflammatory Bowel Disease | 6.9 | 8.1 | -0.17 |
| Insomnia | 1 | 2.1 | -1.1 |
| Intelligence | 1.9 | 0.6 | 2.17 |
| Intracranial aneurysms | 1.4 | 0.3 | 3.67 |
| Irritable Bowel Syndrome | 5.7 | 3.9 | 0.46 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 5.4 | 3 | 0.8 |
| Long COVID | 6.1 | 5.4 | 0.13 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1 | 0.4 | 1.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.4 | 0.6 | 1.33 |
| ME/CFS with IBS | 1.1 | 1.3 | -0.18 |
| ME/CFS without IBS | 1.1 | 0.9 | 0.22 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.5 | 0.8 |
| Metabolic Syndrome | 6.4 | 4.7 | 0.36 |
| Mood Disorders | 8.5 | 5.8 | 0.47 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 3.8 | 5.6 | -0.47 |
| Multiple system atrophy (MSA) | 0.6 | 0.4 | 0.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.2 | -2.2 | |
| Neuropathy (all types) | 0.4 | 2.2 | -4.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.6 | 2.9 | 0.93 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 7 | 5.7 | 0.23 |
| obsessive-compulsive disorder | 5.9 | 3.1 | 0.9 |
| Osteoarthritis | 3.3 | 0.9 | 2.67 |
| Osteoporosis | 1.9 | 0.7 | 1.71 |
| pancreatic cancer | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 6.3 | 6.5 | -0.03 |
| Polycystic ovary syndrome | 6.8 | 2.9 | 1.34 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.3 | 1.4 | -3.67 |
| Primary sclerosing cholangitis | 2.1 | 2.9 | -0.38 |
| Psoriasis | 2.1 | 3.1 | -0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.8 | 3 | 0.93 |
| Rosacea | 0.7 | 0.7 | 0 |
| Schizophrenia | 4.3 | 2.5 | 0.72 |
| scoliosis | 0.8 | 1 | -0.25 |
| Sjögren syndrome | 2.3 | 1.7 | 0.35 |
| Sleep Apnea | 1.3 | 1.6 | -0.23 |
| Slow gastric motility / Gastroparesis | 1.1 | 1.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 1.9 | |
| Stress / posttraumatic stress disorder | 2.3 | 1.6 | 0.44 |
| Systemic Lupus Erythematosus | 4.3 | 1.8 | 1.39 |
| Tic Disorder | 1 | 0.6 | 0.67 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3.7 | 2 | 0.85 |
| Type 2 Diabetes | 6.6 | 5.3 | 0.25 |
| Ulcerative colitis | 5.2 | 6.3 | -0.21 |
| Unhealthy Ageing | 4.8 | 1.9 | 1.53 |
| Vitiligo | 2.2 | 1.2 | 0.83 |
